Navigation Links
First human gets new antibody aimed at hepatitis C virus
Date:8/14/2009

Boston, Mass. Building upon a series of successful preclinical studies, researchers at MassBiologics of the University of Massachusetts Medical School (UMMS) today announced the beginning of a Phase 1 clinical trial, testing the safety and activity of a human monoclonal antibody they developed that can neutralize the Hepatitis C virus (HCV).

The first volunteer received the antibody known as MBL-HCV1 on July 28, 2009, and the study is now proceeding and will eventually involve 30 healthy subjects in a dose-escalation trial expected to conclude later this year. "We are pleased that this program has now entered the clinical trial phase," said Donna Ambrosino, MD, executive director of MassBiologics and a professor of pediatrics at the Medical School. "This trial will test the safety of the antibody and measure its activity in the subjects. This will help us determine the useful dose and other parameters as we plan for the next step in this program, which will be a Phase 2 study in liver transplant patients."

HCV attacks the liver and can eventually lead to liver failure. According to the U.S. Centers for Disease Control and Prevention, 3.2 million Americans are chronically infected with HCV and some 10,000 die annually of the disease. Globally, as many as 170 million people are estimated to suffer from HCV infection. For the most serious cases of HCV that do not respond to antiviral drugs, liver transplantation is the only option.

HCV is the leading indication for liver transplantation, diagnosed in about half of the 6,000 liver transplants done each year in the United States. Transplantation can be a life-saving treatment; however, in nearly all cases the patient's new liver is eventually infected by HCV because the virus remains in the patient's bloodstream during surgery. The powerful antiviral drugs now used to attack HCV prior to end-stage liver failure are not routinely used during surgery due to the patients' weakened condit
'/>"/>

Contact: Michael Cohen
Michael.Cohen@umassmed.edu
508-868-4778
University of Massachusetts Medical School
Source:Eurekalert

Page: 1 2

Related biology technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
3. Kewaunee Scientific Announces First Quarter Results and Quarterly Dividend
4. Genmab Announces 2007 First Half Year Results
5. Pharsight Achieves First License Sale for Public-Source Database
6. Novare Announces First Ever Single Port Laparoscopic Kidney Removal (Nephrectomy) Using RealHand(TM) HD Instruments
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. China Medical Technologies Reports First Quarter Financial Results
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
11. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... 2014 BioClinica®, Inc., a leading provider of ... three of its experts are speaking at the ... to be held September 28 to October 1 in ... also announced the innovative Compass technology, a ... trials acquired earlier this year, is up for the ...
(Date:9/17/2014)... Intarcia Therapeutics, Inc. today announced the presentation ... cost and predictability of non-adherence in type 2 diabetes ... the European Association for the Study of Diabetes (EASD). ... Ph.D., of Analysis Group, Inc. presented data from the ... to characterize the prevalence of non-adherence and serial non-adherence, ...
(Date:9/17/2014)... , Sept. 17, 2014 /PRNewswire/ - SQI Diagnostics Inc. ... develops and commercializes proprietary technologies and products for advanced ... been approved for trading in the United ... is expected to commence on September 17, 2014 on ... continue to trade on the TSX Venture Exchange under ...
(Date:9/17/2014)... LAKE FOREST, California , 17 de ... BB: CYRX) ("la compañía"), principal proveedor mundial ... industria de las ciencias de la vida, ... una compañía de logística global con sede ... a su base de clientes Europa en ...
Breaking Biology Technology:BioClinica to Present at 20th Annual SCDM Conference 2BioClinica to Present at 20th Annual SCDM Conference 3Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 2Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 3Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 4Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 5SQI Diagnostics to begin Trading on the OTCQX Marketplace in the United States 2SQI Diagnostics to begin Trading on the OTCQX Marketplace in the United States 3Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 2Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 3Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 4Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 5
... - Teva Announces Sufficient Funds to Complete Acquisition, ... Pharmaceutical Industries Ltd. (Nasdaq: TEVA ) and Barr,Pharmaceuticals, ... and its,syndicate of lending banks, arranged by Bank of ... permit them to remain in place,following Barr,s acquisition by ...
... call today at 4:30 p.m. ET -, SOUTH ... MGRM ) today reported financial results for the,quarter ... of $16.1 million for the third quarter of,2008, 55% ... 2007. This,growth was driven by revenue from Trofile(TM) for ...
... Calif., Oct. 27 Abaxis, Inc.,(Nasdaq: ABAX ), ... reported financial results for the fiscal,quarter ended September 30, ... of $27.7 million, up 10% over last year,s comparable,quarter., ... 17% over last year,s,comparable quarter., -- Record medical ...
Cached Biology Technology:Teva and Barr Provide Update on Acquisition 2Teva and Barr Provide Update on Acquisition 3Teva and Barr Provide Update on Acquisition 4Teva and Barr Provide Update on Acquisition 5Monogram Announces 2008 Third Quarter Financial Results 2Monogram Announces 2008 Third Quarter Financial Results 3Monogram Announces 2008 Third Quarter Financial Results 4Monogram Announces 2008 Third Quarter Financial Results 5Monogram Announces 2008 Third Quarter Financial Results 6Monogram Announces 2008 Third Quarter Financial Results 7Monogram Announces 2008 Third Quarter Financial Results 8Monogram Announces 2008 Third Quarter Financial Results 9Monogram Announces 2008 Third Quarter Financial Results 10Monogram Announces 2008 Third Quarter Financial Results 11Monogram Announces 2008 Third Quarter Financial Results 12Monogram Announces 2008 Third Quarter Financial Results 13Monogram Announces 2008 Third Quarter Financial Results 14Monogram Announces 2008 Third Quarter Financial Results 15Abaxis Reports Record Revenues and Operating Income for the Second Quarter of Fiscal 2009 2Abaxis Reports Record Revenues and Operating Income for the Second Quarter of Fiscal 2009 3Abaxis Reports Record Revenues and Operating Income for the Second Quarter of Fiscal 2009 4Abaxis Reports Record Revenues and Operating Income for the Second Quarter of Fiscal 2009 5Abaxis Reports Record Revenues and Operating Income for the Second Quarter of Fiscal 2009 6Abaxis Reports Record Revenues and Operating Income for the Second Quarter of Fiscal 2009 7Abaxis Reports Record Revenues and Operating Income for the Second Quarter of Fiscal 2009 8Abaxis Reports Record Revenues and Operating Income for the Second Quarter of Fiscal 2009 9
(Date:9/17/2014)... has learned a great deal about complex social behavior ... have something to teach too. , With their unusually ... cognition, parrots live in a complex social environment---not merely ... bees or ants, but in a dynamic setting of ... most intelligent mammals: dolphins, whales, primates, and social carnivores, ...
(Date:9/16/2014)... morbidity amongst women in Australia is increased by ... today (17 September) in BJOG: An International ... generally enjoy high standards of living; however, existing ... particular between indigenous and non indigenous Australians. , ... impact of socioeconomic position on severe maternal morbidities ...
(Date:9/16/2014)... Hopkins neuroscientists have discovered the "molecular brakes" that time ... cochleas of mice. These "hair cells" translate sound waves ... and are interpreted as sounds. If the arrangement of ... A summary of the research will be published in ... , "The proteins Hey1 and Hey2 act as brakes ...
Breaking Biology News(10 mins):Being social: Learning from the behavior of birds 2New study examines the impact of socioeconomic position & maternal morbidity in Australia 2New study examines the impact of socioeconomic position & maternal morbidity in Australia 3Hey1 and Hey2 ensure inner ear 'hair cells' are made at the right time, in the right place 2
... increase the likelihood of immune complications following bone marrow ... November 22 advance online issue of Nature Genetics ... the donor,s genome but present in the recipient,s, transplants ... known as graft-versus-host disease, in which immune cells from ...
... and technological frontiers. The National Science Foundation has recently ... diverse efforts of the following investigators under the American ... researchers have been awarded grants for investigation of solar ... enhance the capabilities of NJIT,s Big Bear Solar Observatory ...
... to contribute their abstracts to the World Congress on ... meeting devoted to all aspects of osteoporosis and osteoarthritis ... in Florence, Italy from May 5-8, 2010. Beginning ... The submission deadline is February 4, ...
Cached Biology News:Gene mismatch influences success of bone marrow transplants 2Gene mismatch influences success of bone marrow transplants 3Gene mismatch influences success of bone marrow transplants 4NJIT receives NSF funding to improve Big Bear Telescope, study solar energy 2Special sessions announced for World Congress on Osteoporosis 2010 - IOF WCO - ECCEO10 2Special sessions announced for World Congress on Osteoporosis 2010 - IOF WCO - ECCEO10 3
Recognizes NSCL1. The molecular weight of the protein is 14,616 Daltons....
Mouse monoclonal [3G131] to Desmoglein 1 ( Abpromise for all tested applications). entrezGeneID: 1828 SwissProtID: Q02413...
Mouse monoclonal [2D7/1] to E.coli LPS ( Abpromise for all tested applications). Antigen: Tissue / cell preparation: Escherichia coli J5 cells....
COMING SOON: Anti-Mouse C5/C5b, Clone BB5.1. Monoclonal Antibody...
Biology Products: